{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:27:16Z","timestamp":1789014436623,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.lrr.2022.100291","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T11:53:48Z","timestamp":1644234828000},"page":"100291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-7636","authenticated-orcid":false,"given":"James W","family":"Day","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-2295","authenticated-orcid":false,"given":"Thomas A","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-0505","authenticated-orcid":false,"given":"Rajeev","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-5625","authenticated-orcid":false,"given":"Asim","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis D","family":"Kottaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lrr.2022.100291_bib0001","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lrr.2022.100291_bib0002","first-page":"3074","article-title":"Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia","volume":"93","author":"Kiyoi","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2022.100291_bib0003","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/leu.2011.25","article-title":"A new leukemia prognostic scoring system for refractory\/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study","volume":"25","author":"Chevallier","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.lrr.2022.100291_bib0004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/gcc.20531","article-title":"Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis","volume":"47","author":"Ageberg","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"issue":"2","key":"10.1016\/j.lrr.2022.100291_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.12852","article-title":"Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the children's oncology group","volume":"166","author":"Tarlock","year":"2014","journal-title":"Br. J. Haematol"},{"issue":"1","key":"10.1016\/j.lrr.2022.100291_bib0006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.2018.208678","article-title":"Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study","volume":"105","author":"Kayser","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.lrr.2022.100291_bib0007","first-page":"2","article-title":"The challenge of t (6;9) and FLT3-positive acute myelogenous leukemia in a young adult","author":"Song","year":"2014","journal-title":"J. Leuk. (Los Angel)"},{"issue":"5","key":"10.1016\/j.lrr.2022.100291_bib0008","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjh.16433","article-title":"Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission","volume":"189","author":"Diaz-Beya","year":"2020","journal-title":"Br. J. Haematol"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048922000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:09:06Z","timestamp":1761959346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048922000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":8,"alternative-id":["S2213048922000036"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100291","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2022.100291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100291"}}